The Prescrire journal has published its assessment of drugs to avoid in 2025, highlighting 106 drugs with an unfavourable benefit-risk balance. Among them, 88 are currently marketed in France ...

Amgen will charge $6,900 per year for its migraine prevention drug — a price 30 percent lower than Wall Street expectations — as the company attempts to dodge the payer backlash that has ...

NEW YORK, May 10 (Reuters) - Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the fate of WeightWatchers, which declared ...

“Despite taking billions of taxpayer dollars for drug development, these Big Pharma companies unleashed an army of patent attorneys to keep life-saving medicine exclusive and more expensive for ...